Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency
September 24, 2021 16:24 ET
|
OPKO Health, Inc.
NEW YORK and MIAMI, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has extended the...
LeaderMed Group and OPKO Health Form Joint Venture to Develop and Commercialize Oxyntomodulin and Factor VIIa-CTP in China and Other Asian Territories
September 14, 2021 08:00 ET
|
OPKO Health, Inc.; LeaderMed Group
SHANGHAI and MIAMI, Sept. 14, 2021 (GLOBE NEWSWIRE) -- LeaderMed Health Group Limited, a pharmaceutical development company with operations based in Asia, and OPKO Health, Inc. (NASDAQ: OPK), a...
OPKO Health Completes Enrollment in Phase 2 Trial Evaluating RAYALDEE as a Treatment for Symptomatic COVID-19 Outpatients
August 30, 2021 16:17 ET
|
OPKO Health, Inc.
MIAMI, Aug. 30, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces the completion of enrollment in its Phase 2 trial with RAYALDEE® as a treatment for mild-to-moderate COVID-19. The...
OPKO Health to Participate in Two Upcoming Investment Conferences
August 30, 2021 09:04 ET
|
OPKO Health, Inc.
MIAMI, Aug. 30, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in two upcoming virtual investor conferences. 14th Annual Barrington...
OPKO Health Reports 2021 Second Quarter Business Highlights and Financial Results
July 29, 2021 16:05 ET
|
OPKO Health, Inc.
MIAMI, July 29, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended June 30, 2021. Business Highlights ...
OPKO Health to Report Second Quarter 2021 Financial Results on July 29, 2021
July 20, 2021 08:00 ET
|
OPKO Health, Inc.
MIAMI, July 20, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended June 30, 2021, as well as discuss financial...
OPKO Health Licenses Oligonucleotide Therapeutics Platform to CAMP4 Therapeutics
July 12, 2021 08:00 ET
|
OPKO Health, Inc.
MIAMI, July 12, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced it has entered into an exclusive worldwide agreement with privately held CAMP4 Therapeutics Corporation...
OPKO Health to Present at the Ladenburg Thalmann Healthcare Conference
July 08, 2021 16:05 ET
|
OPKO Health, Inc.
MIAMI, July 08, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in the Ladenburg Thalmann Healthcare Conference being held virtually...
OPKO Health Appoints Katherine Stueland as President and CEO of GeneDx
June 22, 2021 08:00 ET
|
OPKO Health, Inc.
MIAMI, June 22, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced the appointment of Katherine Stueland as President and Chief Executive Officer of GeneDx, Inc., the global...
OPKO Health to Develop and Commercialize RAYALDEE® in Greater China with Nicoya Therapeutics
June 21, 2021 08:03 ET
|
OPKO Health, Inc.
MIAMI, June 21, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that its subsidiary EirGen Pharma has entered into an agreement with Nicoya Macau Limited, an affiliate of...